Operating Lease, Right-of-Use Asset of VERTEX PHARMACEUTICALS INC / MA from 01 Jan 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
VERTEX PHARMACEUTICALS INC / MA quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 01 Jan 2019 to 31 Dec 2025.
  • VERTEX PHARMACEUTICALS INC / MA Operating Lease, Right-of-Use Asset for the quarter ending 31 Dec 2025 was $1,562,700,000, a 15% increase year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

VERTEX PHARMACEUTICALS INC / MA Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $1,562,700,000 +$205,900,000 +15% 31 Dec 2025 10-K 13 Feb 2026 2025 FY
Q3 2025 $1,591,800,000 +$195,700,000 +14% 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $1,313,800,000 +$744,000,000 +131% 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $1,338,500,000 +$1,025,600,000 +328% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $1,356,800,000 +$1,063,200,000 +362% 31 Dec 2024 10-K 13 Feb 2026 2025 FY
Q3 2024 $1,396,100,000 +$1,085,600,000 +350% 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $569,800,000 +$245,500,000 +76% 30 Jun 2024 10-Q 02 Aug 2024 2024 Q2
Q1 2024 $312,900,000 -$23,400,000 -7% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $293,600,000 -$53,800,000 -15% 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $310,500,000 -$32,200,000 -9.4% 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $324,300,000 +$6,000,000 +1.9% 30 Jun 2023 10-Q 02 Aug 2023 2023 Q2
Q1 2023 $336,300,000 +$7,300,000 +2.2% 31 Mar 2023 10-Q 02 May 2023 2023 Q1
Q4 2022 $347,400,000 +$17,100,000 +5.2% 31 Dec 2022 10-K 15 Feb 2024 2023 FY
Q3 2022 $342,700,000 +$30,357,000 +9.7% 30 Sep 2022 10-Q 28 Oct 2022 2022 Q3
Q2 2022 $318,300,000 +$1,426,000 +0.45% 30 Jun 2022 10-Q 05 Aug 2022 2022 Q2
Q1 2022 $329,000,000 +$6,681,000 +2.1% 31 Mar 2022 10-Q 06 May 2022 2022 Q1
Q4 2021 $330,300,000 +$4,700,000 +1.4% 31 Dec 2021 10-K 10 Feb 2023 2022 FY
Q3 2021 $312,343,000 +$55,543,000 +22% 30 Sep 2021 10-Q 03 Nov 2021 2021 Q3
Q2 2021 $316,874,000 30 Jun 2021 10-Q 30 Jul 2021 2021 Q2
Q1 2021 $322,319,000 31 Mar 2021 10-Q 30 Apr 2021 2021 Q1
Q4 2020 $325,600,000 +$237,398,000 +269% 31 Dec 2020 10-K 09 Feb 2022 2021 FY
Q3 2020 $256,800,000 +$195,871,000 +321% 30 Sep 2020 10-Q 30 Oct 2020 2020 Q3
Q4 2019 $88,202,000 +$26,528,000 +43% 31 Dec 2019 10-K 11 Feb 2021 2020 FY
Q3 2019 $60,929,000 30 Sep 2019 10-Q 31 Oct 2019 2019 Q3
Q2 2019 $58,031,000 30 Jun 2019 10-Q 01 Aug 2019 2019 Q2
Q1 2019 $60,573,000 31 Mar 2019 10-Q 01 May 2019 2019 Q1
Q4 2018 $61,674,000 01 Jan 2019 10-Q 31 Oct 2019 2019 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.